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mor in patients undergoing curative resection of lung
cancer.1 The data set included 202 patients with all
histologic types of lung cancer who had had their tumor
resected for cure but died of all causes, including post-
operative complications, within 30 days of surgery. At
autopsy, residual cancer was observed in 35% of the
patients. Of the 19 patients with small cell lung cancer
(SCLC), however, 13 (70%) had residual disease (pre-
sent at distant sites in 12 of 13). Although the number of
patients was small, this paper changed how clinicians
thought about SCLC. The initial sensitivity of SCLC to
chemotherapy and radiotherapy was recognized by
Watson and Berg.2 Other clinical3 and laboratory
studies4 established SCLC as a distinct clinicopathologic
entity. Indeed, SCLC and non-SCLC (NSCLC) are generally
discussed as separate topics. After 50 years of investi-
gation, it is recognized that there are many similarities as
well as differences between the therapeutic principles of
treatment of the two diseases.
For operable cases without mediastinal lymph node
involvement, surgical resection followed by assessment
for adjuvant chemotherapy is recommended. The stan-
dard of care for unresectable locally advanced SCLC and
NSCLC is early concurrent chemoradiation. For both lung
cancer subtypes, cisplatin-etoposide as the chemo-
therapy component of combined modality therapy has
never been demonstrated to be inferior to any other
regimen. The median survival for locally advanced dis-
ease with initial chemoradiation is approximately the
same, with a median survival time of 20 to 24 months
and a 5-year survival rate of 20%.
For metastatic disease, the palliative ﬁrst-line sys-
temic therapy for patients with SCLC and NSCLC without
a targetable driver mutation is a platinum-based two-
drug chemotherapy combination. For SCLC, platinum
and etoposide has generally prevailed as the standard,
although platinum plus irinotecan is widely used in Asia.
The platinum doublet used for ﬁrst-line chemotherapy
for NSCLC has had a more complex evolution withimproved survival with modern platinum doublets can
be questioned even for nonsquamous cancers.5 In both
pathologic types, single agents or dose attenuation with
ﬁrst-line therapy result in inferior outcomes. Three- and
four-drug chemotherapy regimens are not better than
two-drug regimens. Dose-dense and high-dose cytotoxic
regimens do not generate superior survival results.
Nonplatinum regimens are not superior to platinum-
based two-drug combinations. Four to six cycles of
ﬁrst-line therapy is sufﬁcient for most patients. Mainte-
nance chemotherapy is not recommended for SCLC,
whereas it is an option for NSCLC that confers a survival
advantage if patients fail to receive second-line therapy.6
Second-line treatment for both types of lung cancer is
single-agent chemotherapy. Topoisomerase-1 inhibitors
have been extensively investigated and used in SCLC.
Docetaxel is standard second-line therapy for squamous
cancers, whereas docetaxel and pemetrexed have equal
efﬁcacy in second-line chemotherapy for nonsquamous
cancers.6 The survival outcome for metastatic SCLC and
metastatic NSCLC (without epidermal growth factor re-
ceptor gene [EGFR] or anaplastic lymphoma receptor
tyrosine kinase gene [ALK] mutations) is similar, with a
median survival time of 11 to 12 months and a 2-year
survival rate of 15% to 20%.5 The discovery of molec-
ular targets in adenocarcinomas that are treatable with
approved drugs is a conspicuous difference betweenJournal of Thoracic Oncology Vol. 11 No. 2: 139-141
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lecular targets that can be treated with drugs with
proven efﬁcacy have as yet been approved for SCLC.7
Although the initial response rate to chemotherapy
for advanced SCLC of 60% to 70% is approximately
double that for NSCLC, the median time for
chemotherapy-resistant clones to cause a fatal outcome
is approximately the same for both diseases. However,
the natural history of metastatic lung cancer unre-
strained by any systemic treatment is much worse for
SCLC than for NSCLC. The propensity of SCLC for rapid
growth and spread is demonstrated in a different way in
an article by Silva et al.8 on outcome of SCLC detected by
low-dose computed tomography screening (LDCT) for
lung cancer that accompanies this editorial.
In a population of 5134 heavy smokers from Italy, 10
cases of SCLC were reported (eight in the screened group
and two in the control group) over 45,141 person-years
(22 per 100,000 person-years). The rate of cases of SCLC
among all lung cancers diagnosed by screening was 10 in
164 (6%). Cumulative tobacco consumption was 82
pack-years compared with 46 pack-years for NSCLC. The
patients with SCLC were somewhat older, with a median
age at diagnosis of 65 years compared with 57 years for
patients with NSCLC. Six of the eight cases of SCLC in the
screened group were asymptomatic. Despite this, most of
the neoplasms (seven of 10) had distant spread. Stage Ia
disease was found in only one individual; two others had
stage III disease. Two patients were treated surgically
with lobectomy plus chemotherapy, but both relapsed.
Although this is a small data set, poignantly, there were
no 3-year survivors.
The large 55,452-patient National Lung Screening
Trial showed evidence of a differential beneﬁt by histo-
logic ﬁnding of LDCT screening.9 The 6-year lung cancer
survival rate for adenocarcinoma cases speciﬁcally was
71.6% for the LDCT screening arm versus 54.5% in the
chest radiography screening arm (p < 0.0001). Survival
rates for all cases of nonsquamous NSCLC were similar
to that for adenocarcinoma, with a mortality risk ratio of
0.71, thus demonstrating a substantial beneﬁt of LDCT
screening. In contrast, for SCLC, which accounted for
13% of all cancers found in the LDCT arm and 34% of all
interval cancers in the study, the 6-year survival in the
LDCT arm (n ¼ 143) was 14.4% versus 11.5% in the
control arm (n ¼ 163, mortality risk ratio ¼ 0.9; 95%
conﬁdence interval: 0.69–1.18). No survival beneﬁt of
screening was observed. Cuffe et al.10 combined the
Toronto and Mayo Clinic screening studies and had
clinical data on 10 cases of SCLC identiﬁed by LDCT
screening. One of the six patients with limited-stage
disease was suitable for surgical resection, and two pa-
tients were disease free at 2 and 9 years. The median
survival was 11.3 months. Another 10 cases of SCLCwere detected by the Pan-Canadian Lung Cancer
Screening Project (Stephen Lam unpublished data). Me-
dian smoking exposure was 56 pack-years and 7 of 10
patients were male. Six had limited-stage disease. The
two patients (20%) who had peripheral lung tumors
suitable for surgical resection are alive 1.2 and 4.8 years
after diagnosis. The median survival of this group is 22
months, which is the same as in the report by Silva et al.
The slightly longer survival times in these studies are
probably related to lead-time bias and small sample size.
The available information supports the widely held
belief that LDCT screening is ineffective in reducing
mortality due to SCLC. There will be a minority of cases
in which a more peripheral SCLC is identiﬁed, and if
nodal staging is negative, individual lives may be saved
by surgical resection and adjuvant chemotherapy. Oc-
casional patients may be cured by the standard com-
bined modality regimen, but that proportion continues
to be approximately 20% of patients with limited-stage
disease. These are very slim pickings. A more effective
screening strategy must await an improvement in tech-
nology such as discovery of the elusive biomarker.
Much has changed since Matthews’ 1973 lung cancer
autopsy paper.1 Modern preoperative staging paradigms
are much more effective in detection of metastases.
Although improvement in systemic therapy has been
frustratingly slow, combined modality therapy with early
concurrent thoracic irradiation and later prophylactic
brain irradiation has modestly improved prospects for
long-term survival in locally advanced SCLC.11 The thera-
peutic principles of systemic treatment of SCLC andNSCLC
may be converging again, with immunotherapy becom-
ing the most exciting advance in both histologic types.
Some things have not changed. The virulent natural
history of SCLC for rapid growth and spread is as bad as
before. Between 60% and 80% of the participants in the
Italian, U.S., and Canadian screening studies with SCLC
were current smokers. Smoking cessation as part of
LDCT screening for lung cancer is essential.
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